Inflammation plays a critical role in the development of insulin resistance and type 2 diabetes (T2D). Historical evidence, including the use of high-dose salicylates to lower blood glucose in diabetic patients, suggests a link between inflammation and T2D. Recent studies have shown that inflammation, particularly through the activation of the IKKβ/NF-κB and JNK pathways, contributes to insulin resistance. These pathways are activated by various factors, including proinflammatory cytokines, microbial products, and cellular stressors such as oxidative stress and endoplasmic reticulum (ER) stress. Inflammation in adipose tissue leads to the production of proinflammatory cytokines, which further exacerbate insulin resistance and T2D. Inflammation is also closely linked to atherosclerosis, suggesting that inflammation may be a common factor in the pathogenesis of obesity-related diseases. The mechanisms of inflammation-induced insulin resistance involve both transcriptional and post-translational modifications. For example, JNK promotes insulin resistance by phosphorylating insulin receptor substrate-1 (IRS-1) at serine residues, while IKKβ activates NF-κB, leading to the expression of proinflammatory genes that contribute to insulin resistance. The liver is also affected by obesity and inflammation, with proinflammatory cytokines and fatty acids contributing to hepatic insulin resistance and non-alcoholic fatty liver disease (NAFLD). Inflammation in adipose tissue leads to the recruitment of macrophages, which further promote inflammation and insulin resistance. The liver is densely populated with Kupffer cells, which can be activated by inflammation, contributing to insulin resistance and atherosclerosis. Several anti-inflammatory strategies are being explored, including the use of salicylates, thiazolidinediones (TZDs), and statins. These drugs have anti-inflammatory properties and may help improve insulin sensitivity and reduce the risk of T2D and cardiovascular disease. However, the effectiveness of these strategies in treating insulin resistance and T2D is still under investigation. Future research aims to develop targeted therapies that address the inflammatory processes underlying insulin resistance and T2D.Inflammation plays a critical role in the development of insulin resistance and type 2 diabetes (T2D). Historical evidence, including the use of high-dose salicylates to lower blood glucose in diabetic patients, suggests a link between inflammation and T2D. Recent studies have shown that inflammation, particularly through the activation of the IKKβ/NF-κB and JNK pathways, contributes to insulin resistance. These pathways are activated by various factors, including proinflammatory cytokines, microbial products, and cellular stressors such as oxidative stress and endoplasmic reticulum (ER) stress. Inflammation in adipose tissue leads to the production of proinflammatory cytokines, which further exacerbate insulin resistance and T2D. Inflammation is also closely linked to atherosclerosis, suggesting that inflammation may be a common factor in the pathogenesis of obesity-related diseases. The mechanisms of inflammation-induced insulin resistance involve both transcriptional and post-translational modifications. For example, JNK promotes insulin resistance by phosphorylating insulin receptor substrate-1 (IRS-1) at serine residues, while IKKβ activates NF-κB, leading to the expression of proinflammatory genes that contribute to insulin resistance. The liver is also affected by obesity and inflammation, with proinflammatory cytokines and fatty acids contributing to hepatic insulin resistance and non-alcoholic fatty liver disease (NAFLD). Inflammation in adipose tissue leads to the recruitment of macrophages, which further promote inflammation and insulin resistance. The liver is densely populated with Kupffer cells, which can be activated by inflammation, contributing to insulin resistance and atherosclerosis. Several anti-inflammatory strategies are being explored, including the use of salicylates, thiazolidinediones (TZDs), and statins. These drugs have anti-inflammatory properties and may help improve insulin sensitivity and reduce the risk of T2D and cardiovascular disease. However, the effectiveness of these strategies in treating insulin resistance and T2D is still under investigation. Future research aims to develop targeted therapies that address the inflammatory processes underlying insulin resistance and T2D.